<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291109</url>
  </required_header>
  <id_info>
    <org_study_id>9298</org_study_id>
    <nct_id>NCT00291109</nct_id>
  </id_info>
  <brief_title>An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg</brief_title>
  <official_title>Quantitative Real Time PCR in Cytolytic Formalin Fixed Breast Cells Obtained by Periareolar Fine Needle Aspiration. An Ancillary Protocol to a Chemoprevention Trial of Letrozole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <brief_summary>
    <textblock>
      To assess the quantitative real time PCR results of oligonucleotide probes for a number of
      gene transcription products that may be useful as predictors or indicators of response to
      letrozole
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the quantitative real time PCR results of oligonucleotide probes for a number of
      gene transcription products (PCNA, cyclin-D1, ER alpha, PR, pS2, 450 aromatase, bcl-2, bax,
      caspase-3, and VEGFR) that may be useful as predictors or indicators of response to letrozole
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date>July 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole 2.5 mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  evidence of hyperplasia with/without atypia upon random periareolar fine needle
             aspiration of breast

          -  on hormone replacement therapy

          -  postmenopausal

          -  increased risk of developing breast cancer based on personal or family history

          -  never have taken aromatase inhibitors or selective estrogen receptor modulators in
             last six months

          -  women who have a high risk of breast cancer

          -  older than 18 years

        Exclusion Criteria:

          -  no anticoagulants

          -  no marked breast tenderness

          -  not pregnant or within twelve months of breast feeding/childbirth
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol J Fabian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <last_update_submitted>September 15, 2008</last_update_submitted>
  <last_update_submitted_qc>September 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2008</last_update_posted>
  <keyword>breast atypia</keyword>
  <keyword>breast epithelial hyperplasia</keyword>
  <keyword>Ki-67</keyword>
  <keyword>RTPCR</keyword>
  <keyword>microdissection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

